Suppression of tumour necrosis factor-α by Schizonepeta tenuifolia water extract via inhibition of IκBα degradation and Jun N-terminal kinase/stress-activated protein kinase activation

Journal of Pharmacy and Pharmacology

Volumn 62, Issue 8, 2010, Pages 1069-1076

  Kang, Hee ^a   Han, Sang Woo ^a   Hong, Joung Woo ^a   Sohn, Nak Won ^a  

^a Kyung Hee University   (South Korea)

Author keywords

I B ; Jun N terminal kinase stress activated protein kinase; macrophages; Schizonepeta tenuifolia; tumour necrosis factor

Indexed keywords

I KAPPA B ALPHA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; PLANT EXTRACT; PROTEIN C JUN; SCHIZONEPETA TENUIFOLIA EXTRACT; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOTAGMIN I; THIOGLYCOLIC ACID; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD SAMPLING; C57BL 6 MOUSE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; IN VITRO STUDY; IN VIVO STUDY; MALE; MEDICINAL PLANT; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; SCHIZONEPETA TENUIFOLIA;

ACTIVATING TRANSCRIPTION FACTOR 2; ACTIVE TRANSPORT, CELL NUCLEUS; ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS; BLOTTING, WESTERN; CELLS, CULTURED; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; ENZYME ACTIVATION; I-KAPPA B PROTEINS; INFLAMMATION; INTERLEUKIN-6; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LAMIACEAE; LIPOPOLYSACCHARIDES; MACROPHAGES, PERITONEAL; MALE; MICE; MICE, INBRED C57BL; PHOSPHORYLATION; PLANT EXTRACTS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS C-JUN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TIME FACTORS; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77954922229     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2010.01126.x     Document Type: Article

References (44)

1. D'Acquisto F et al. Inhibition of nuclear factor kappa B (NF-B): an emerging theme in anti-inflammatory therapies. Mol Interv 2002 2 : 22 35.
2. Ramadori G et al. Interleukin 6, the third mediator of acute-phase reaction, modulates hepatic protein synthesis in human and mouse. Comparison with interleukin 1 beta and tumor necrosis factor-alpha. Eur J Immunol 1988 18 : 1259 1264.
3. Karin M. The regulation of AP-1 activity by mitogen-activated protein kinases. J Biol Chem 1995 270 : 16483 16486.
4. Geppert TD et al. Lipopolysaccharide signals activation of tumor necrosis factor biosynthesis through the ras/raf-1/MEK/MAPK pathway. Mol Med 1994 1 : 93 103.
5. Lee JC et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994 372 : 739 746.
6. Swantek JL et al. Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) is required for lipopolysaccharide stimulation of tumor necrosis factor alpha (TNF-alpha) translation: glucocorticoids inhibit TNF-alpha translation by blocking JNK/SAPK. Mol Cell Biol 1997 17 : 6274 6282.
7. Fung D, Lau CB. Schizonepeta tenuifolia: chemistry, pharmacology, and clinical applications. J Clin Pharmacol 2002 42 : 30 36.
8. Shin TY et al. Effect of Schizonepeta tenuifolia extract on mast cell-mediated immediate-type hypersensitivity in rats. Immunopharmacol Immunotoxicol 1999 21 : 705 715.
9. Kang H et al. Immunomodulatory effect of Schizonepeta tenuifolia water extract on mouse Th1/Th2 cytokine production in-vivo and in-vitro. J Pharm Pharmacol 2008 60 : 901 907.
10. Kim SJ et al. Anti-inflammatory activity of Schizonepeta tenuifolia through the inhibition of MAPK phosphorylation in mouse peritoneal macrophages. Am J Chin Med 2008 36 : 1145 1158.
11. Elias JA, Lentz V. IL-1 and tumor necrosis factor synergistically stimulate fibroblast IL-6 production and stabilize IL-6 messenger RNA. J Immunol 1990 145 : 161 166.
12. Snyers L et al. Glucocorticoid up-regulation of high-affinity interleukin 6 receptors on human epithelial cells. Proc Natl Acad Sci U S A 1990 87 : 2838 2842.
13. Hayden MS, Ghosh S. Signaling to NF-kappaB. Genes Dev 2004 18 : 2195 2224.
14. Sun SC et al. NF-kappa B controls expression of inhibitor I kappa B alpha: evidence for an inducible autoregulatory pathway. Science 1993 259 : 1912 1915.
15. Chiao PJ et al. Autoregulation of I kappa B alpha activity. Proc Natl Acad Sci U S A 1994 91 : 28 32.
16. Auphan N et al. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 1995 270 : 286 290.
17. Schacke H et al. Selective glucocorticoid receptor agonists (SEGRAs): novel ligands with an improved therapeutic index. Mol Cell Endocrinol 2007 275 : 109 117.
18. Rhoades KL et al. The regulation of the human tumor necrosis factor alpha promoter region in macrophage, T cell, and B cell lines. J Biol Chem 1992 267 : 22102 22107.
19. Gaestel M et al. Targeting innate immunity protein kinase signalling in inflammation. Nat Rev Drug Discov 2009 8 : 480 499.
20. Guha M, Mackman N. LPS induction of gene expression in human monocytes. Cell Signal 2001 13 : 85 94.
21. Dower SK, Qwarnstrom EE. Signalling networks, inflammation and innate immunity. Biochem Soc Trans 2003 31 : 1462 1471.
22. Swinney DC et al. A small molecule ubiquitination inhibitor blocks NF-kappa B-dependent cytokine expression in cells and rats. J Biol Chem 2002 277 : 23573 23581.
23. Hess J et al. AP-1 subunits: quarrel and harmony among siblings. J Cell Sci 2004 117 : 5965 5973.
24. Joyce DA et al. Targets of glucocorticoid action on TNF-alpha release by macrophages. Inflamm Res 2001 50 : 337 340.
25. Sironi M et al. Differential sensitivity of in vivo TNF and IL-6 production to modulation by anti-inflammatory drugs in mice. Int J Immunopharmacol 1992 14 : 1045 1050.
26. Barber AE et al. Glucocorticoid therapy alters hormonal and cytokine responses to endotoxin in man. J Immunol 1993 150 : 1999 2006.
27. Choy EH et al. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum 2002 46 : 3143 3150.
28. Ito H et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 2004 126 : 989 996.
29. Tilg H et al. Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood 1994 83 : 113 118.
30. Zhou Xing JG et al. IL-6 is an inflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest 1998 101 : 311 320.
31. Beverly E. Barton JVJ. Protective role of interleukin 6 in the lipopolysaccharide-galactosamine septic shock model. Infect Immun 1993 61 : 1496 1499.
32. Dan Aderka JL, Jan Vilcek. IL-6 inhibits lipopolysaccharide-induced tumor necrosis factor production in cultured human monocytes, U937 cells, and in mice. J Immunol 1989 143 : 3517 3523.
33. Kim K et al. MEKK3 is essential for lipopolysaccharide-induced interleukin-6 and granulocyte-macrophage colony-stimulating factor production in macrophages. Immunology 2007 120 : 242 250.
34. Lee IK et al. Phytochemical constituents of Schizonepeta tenuifolia Briquet. Natural Product Sciences 2008 14 : 100 106.
35. Ikeda Y et al. Ursolic acid: an anti- and pro-inflammatory triterpenoid. Mol Nutr Food Res 2008 52 : 26 42.
36. Xagorari A et al. Luteolin inhibits an endotoxin-stimulated phosphorylation cascade and proinflammatory cytokine production in macrophages. J Pharmacol Exp Ther 2001 296 : 181 187.
37. Xagorari A et al. Inhibition of LPS-stimulated pathways in macrophages by the flavonoid luteolin. Br J Pharmacol 2002 136 : 1058 1064.
38. Kotanidou A et al. Luteolin reduces lipopolysaccharide-induced lethal toxicity and expression of proinflammatory molecules in mice. Am J Respir Crit Care Med 2002 165 : 818 823.
39. Yeh CC et al. The immunomodulation of endotoxin-induced acute lung injury by hesperidin in vivo and in vitro. Life Sci 2007 80 : 1821 1831.
40. Li R et al. Suppression of adjuvant arthritis by hesperidin in rats and its mechanisms. J Pharm Pharmacol 2008 60 : 221 228.
41. Osakabe N et al. Rosmarinic acid inhibits epidermal inflammatory responses: anticarcinogenic effect of Perilla frutescens extract in the murine two-stage skin model. Carcinogenesis 2004 25 : 549 557.
42. Lee J et al. R osmarinic acid as a downstream inhibitor of IKK-beta in TNF-alpha-induced upregulation of CCL11 and CCR3. Br J Pharmacol 2006 148 : 366 375.
43. Lee J et al. Effect of rosmarinic acid on atopic dermatitis. J Dermatol 2008 35 : 768 771.
44. Kim HK et al. Rosmarinic acid down-regulates the LPS-induced production of monocyte chemoattractant protein-1 (MCP-1) and macrophage inflammatory protein-1alpha (MIP-1alpha) via the MAPK pathway in bone-marrow derived dendritic cells. Mol Cells 2008 26 : 583 589.